West Retained Earnings from 2010 to 2025

WST Stock

USD 225.80 6.10 2.63%

West Pharmaceutical Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that West Pharmaceutical Services retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1985-12-31

Previous Quarter

3.9 B

Current Value

4 B

Quarterly Volatility

909.4 M

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check West Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among West Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 163.2 M, Total Revenue of 3 B or Gross Profit of 1 B, as well as many indicators such as Price To Sales Ratio of 8.68, Dividend Yield of 0.0023 or PTB Ratio of 9.36. West financial statements analysis is a perfect complement when working with West Pharmaceutical Valuation or Volatility modules.

Check out the analysis of West Pharmaceutical Correlation against competitors.

Latest West Pharmaceutical's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of West Pharmaceutical Services over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. West Pharmaceutical's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in West Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 3.96 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

West Retained Earnings Regression Statistics

	Arithmetic Mean	1,765,489,375
	Geometric Mean	1,314,007,057
	Coefficient Of Variation	71.59
	Mean Deviation	1,041,586,719
	Median	1,353,400,000
	Standard Deviation	1,263,952,351
	Sample Variance	1597575.5T
	Range	4B
	R-Value	0.95
	Mean Square Error	179564.5T
	R-Squared	0.90
	Slope	251,172,132
	Total Sum of Squares	23963633.2T

West Retained Earnings History

	2025	4.2 B
	2024	4 B
	2023	3.5 B
	2022	3 B
	2021	2.5 B
	2020	1.8 B
	2019	1.5 B

Other Fundumenentals of West Pharmaceutical

Retained Earnings Total Equity

West Pharmaceutical Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.78	0.95	0.98	0.78	0.97	0.34	-0.43	0.98	0.57	-0.46	0.47	-0.87	0.96	0.18	0.88	0.95	-0.62	0.52	0.65	0.85	-0.93	0.59	0.88	0.92	0.9	-0.5
Total Stockholder Equity	0.98		-0.84	0.97	0.99	0.69	0.98	0.33	-0.56	0.97	0.58	-0.58	0.36	-0.92	0.96	0.08	0.87	0.98	-0.7	0.59	0.64	0.86	-0.96	0.59	0.9	0.94	0.92	-0.51
Net Debt	-0.78	-0.84		-0.73	-0.8	-0.45	-0.89	-0.37	0.65	-0.78	-0.52	0.73	-0.08	0.87	-0.67	0.07	-0.76	-0.78	0.67	-0.58	-0.64	-0.86	0.91	-0.25	-0.85	-0.86	-0.92	0.1
Retained Earnings	0.95	0.97	-0.73		0.97	0.68	0.9	0.26	-0.6	0.93	0.46	-0.56	0.26	-0.92	0.96	0.1	0.86	0.99	-0.63	0.48	0.63	0.77	-0.89	0.74	0.88	0.93	0.86	-0.68
Net Receivables	0.98	0.99	-0.8	0.97		0.73	0.97	0.26	-0.54	0.98	0.56	-0.51	0.38	-0.91	0.97	0.14	0.89	0.98	-0.67	0.57	0.66	0.86	-0.96	0.58	0.9	0.92	0.9	-0.56
Total Liab	0.78	0.69	-0.45	0.68	0.73		0.74	0.15	0.02	0.75	0.19	0.03	0.5	-0.6	0.68	0.68	0.79	0.66	-0.03	0.01	0.75	0.7	-0.61	0.45	0.69	0.72	0.71	-0.38
Total Current Assets	0.97	0.98	-0.89	0.9	0.97	0.74		0.36	-0.47	0.96	0.58	-0.53	0.4	-0.9	0.9	0.16	0.87	0.92	-0.64	0.55	0.69	0.9	-0.97	0.47	0.91	0.94	0.96	-0.35
Short Term Debt	0.34	0.33	-0.37	0.26	0.26	0.15	0.36		-0.08	0.32	0.17	-0.51	0.22	-0.31	0.24	-0.07	0.13	0.23	-0.27	0.17	0.21	0.23	-0.31	0.31	0.27	0.35	0.31	0.15
Intangible Assets	-0.43	-0.56	0.65	-0.6	-0.54	0.02	-0.47	-0.08		-0.45	-0.2	0.83	0.47	0.73	-0.46	0.42	-0.52	-0.65	0.63	-0.5	-0.35	-0.48	0.59	-0.41	-0.57	-0.59	-0.55	0.44
Accounts Payable	0.98	0.97	-0.78	0.93	0.98	0.75	0.96	0.32	-0.45		0.62	-0.48	0.48	-0.85	0.96	0.13	0.87	0.94	-0.67	0.61	0.65	0.87	-0.95	0.55	0.87	0.88	0.86	-0.49
Common Stock	0.57	0.58	-0.52	0.46	0.56	0.19	0.58	0.17	-0.2	0.62		-0.29	0.58	-0.35	0.62	-0.23	0.35	0.48	-0.77	0.85	0.13	0.55	-0.64	0.08	0.48	0.4	0.39	0.0
Long Term Debt	-0.46	-0.58	0.73	-0.56	-0.51	0.03	-0.53	-0.51	0.83	-0.48	-0.29		0.27	0.7	-0.43	0.49	-0.45	-0.59	0.68	-0.53	-0.33	-0.5	0.63	-0.41	-0.56	-0.6	-0.57	0.18
Good Will	0.47	0.36	-0.08	0.26	0.38	0.5	0.4	0.22	0.47	0.48	0.58	0.27		-0.04	0.49	0.34	0.16	0.22	-0.22	0.32	0.07	0.27	-0.34	0.02	0.18	0.17	0.18	0.0
Treasury Stock	-0.87	-0.92	0.87	-0.92	-0.91	-0.6	-0.9	-0.31	0.73	-0.85	-0.35	0.7	-0.04		-0.82	-0.09	-0.86	-0.95	0.58	-0.43	-0.74	-0.83	0.89	-0.57	-0.93	-0.96	-0.94	0.48
Property Plant Equipment	0.96	0.96	-0.67	0.96	0.97	0.68	0.9	0.24	-0.46	0.96	0.62	-0.43	0.49	-0.82		0.1	0.79	0.95	-0.7	0.6	0.53	0.75	-0.9	0.62	0.81	0.84	0.79	-0.63
Current Deferred Revenue	0.18	0.08	0.07	0.1	0.14	0.68	0.16	-0.07	0.42	0.13	-0.23	0.49	0.34	-0.09	0.1		0.18	0.07	0.57	-0.52	0.55	0.12	0.01	0.06	0.2	0.2	0.2	-0.02
Short Term Investments	0.88	0.87	-0.76	0.86	0.89	0.79	0.87	0.13	-0.52	0.87	0.35	-0.45	0.16	-0.86	0.79	0.18		0.89	-0.45	0.41	0.74	0.93	-0.86	0.51	0.88	0.89	0.88	-0.5
Net Tangible Assets	0.95	0.98	-0.78	0.99	0.98	0.66	0.92	0.23	-0.65	0.94	0.48	-0.59	0.22	-0.95	0.95	0.07	0.89		-0.66	0.53	0.65	0.82	-0.92	0.67	0.9	0.93	0.89	-0.64
Long Term Debt Total	-0.62	-0.7	0.67	-0.63	-0.67	-0.03	-0.64	-0.27	0.63	-0.67	-0.77	0.68	-0.22	0.58	-0.7	0.57	-0.45	-0.66		-0.91	-0.1	-0.55	0.75	-0.29	-0.55	-0.53	-0.53	0.28
Capital Surpluse	0.52	0.59	-0.58	0.48	0.57	0.01	0.55	0.17	-0.5	0.61	0.85	-0.53	0.32	-0.43	0.6	-0.52	0.41	0.53	-0.91		0.05	0.57	-0.71	0.04	0.44	0.37	0.39	-0.13
Deferred Long Term Liab	0.65	0.64	-0.64	0.63	0.66	0.75	0.69	0.21	-0.35	0.65	0.13	-0.33	0.07	-0.74	0.53	0.55	0.74	0.65	-0.1	0.05		0.76	-0.61	0.39	0.84	0.8	0.77	-0.18
Long Term Investments	0.85	0.86	-0.86	0.77	0.86	0.7	0.9	0.23	-0.48	0.87	0.55	-0.5	0.27	-0.83	0.75	0.12	0.93	0.82	-0.55	0.57	0.76		-0.91	0.29	0.91	0.87	0.88	-0.2
Accumulated Depreciation	-0.93	-0.96	0.91	-0.89	-0.96	-0.61	-0.97	-0.31	0.59	-0.95	-0.64	0.63	-0.34	0.89	-0.9	0.01	-0.86	-0.92	0.75	-0.71	-0.61	-0.91		-0.4	-0.88	-0.89	-0.91	0.37
Short Long Term Debt	0.59	0.59	-0.25	0.74	0.58	0.45	0.47	0.31	-0.41	0.55	0.08	-0.41	0.02	-0.57	0.62	0.06	0.51	0.67	-0.29	0.04	0.39	0.29	-0.4		0.51	0.61	0.43	-0.76
Cash And Equivalents	0.88	0.9	-0.85	0.88	0.9	0.69	0.91	0.27	-0.57	0.87	0.48	-0.56	0.18	-0.93	0.81	0.2	0.88	0.9	-0.55	0.44	0.84	0.91	-0.88	0.51		0.97	0.93	-0.32
Net Invested Capital	0.92	0.94	-0.86	0.93	0.92	0.72	0.94	0.35	-0.59	0.88	0.4	-0.6	0.17	-0.96	0.84	0.2	0.89	0.93	-0.53	0.37	0.8	0.87	-0.89	0.61	0.97		0.97	-0.41
Net Working Capital	0.9	0.92	-0.92	0.86	0.9	0.71	0.96	0.31	-0.55	0.86	0.39	-0.57	0.18	-0.94	0.79	0.2	0.88	0.89	-0.53	0.39	0.77	0.88	-0.91	0.43	0.93	0.97		-0.31
Capital Stock	-0.5	-0.51	0.1	-0.68	-0.56	-0.38	-0.35	0.15	0.44	-0.49	0.0	0.18	0.0	0.48	-0.63	-0.02	-0.5	-0.64	0.28	-0.13	-0.18	-0.2	0.37	-0.76	-0.32	-0.41	-0.31

Click cells to compare fundamentals

About West Pharmaceutical Financial Statements

West Pharmaceutical shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although West Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. The changes in West Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses on on West Pharmaceutical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	4 B	4.2 B
Retained Earnings Total Equity	3.4 B	3.6 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC